Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium isoglycyrrhizinate in HBV-related acute-on-chronic liver failure
ChiCTR-IPC-15007248Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Magnesium isoglycyrrhizinate in acute-on-chronic liver failure (ACLF) and hepatitis B (HBV) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Cytokine levels and Mortality rate. Started Oct 2015; status: recruiting.
02
Drugs
Magnesium isoglycyrrhizinate
03
Conditions
acute-on-chronic liver failure (ACLF)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-IPC-15007248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-15007248.